Alkem MedTech Private Limited, a wholly-owned subsidiary of Alkem Laboratories Limited, has announced a binding offer to acquire up to 55% stake in Swiss medical device company Occlutech Holding AG, marking the pharmaceutical company's strategic entry into the cardiovascular devices segment.

Acquisition Details

Through a binding offer executed on February 13, 2026, Alkem MedTech has proposed to acquire up to 55% of Occlutech Holding AG's equity share capital. The updated transaction parameters reflect the strategic importance of this acquisition:

Target Company Profile and Performance

Occlutech Holding AG, incorporated on December 12, 2000, is a Swiss medical device company specializing in minimally invasive cardiac implants for congenital heart defects, stroke prevention, and heart failure. The company holds the position as Europe's second-largest player in minimally invasive cardiac implants and third-largest globally.

Financial Performance Trajectory

Occlutech's financial performance demonstrates consistent growth with recent revenue expansion:

The company recorded EUR 49.40 million in revenue for calendar year 2025, representing a 15.7% compound annual growth rate over three years. Occlutech derives approximately 85% of its revenue from Europe and the United States.

Strategic Rationale and Market Position

The acquisition enables Alkem MedTech's entry into advanced cardiovascular devices, leveraging Occlutech's established global presence across over 80 countries. The target company operates manufacturing and R&D facilities in Germany and Turkey, with a global distribution hub in Sweden and clinical operations in the United States.

Executive Chairman B.N. Singh of Alkem Laboratories stated that the acquisition reinforces the company's long-term vision of becoming a global medical devices player. Kaustav Banerjee, CEO of Alkem MedTech, highlighted Occlutech's established capabilities and strong foundation for sustainable growth in high-barrier, high-value markets.

Regulatory Framework and Timeline

The transaction requires statutory approvals including foreign direct investment clearances in Italy and Sweden, with precautionary filing in France. The acquisition remains subject to definitive agreements, fulfillment of conditions precedent, and regulatory authorizations. Boston Consulting Group acted as advisor for this transaction, with completion expected by June 2026 following regulatory approvals.

Alkem Laboratories has formalized its corporate restructuring initiative with the board of directors of Alkem Medtech Private Limited officially approving the merger on February 6, 2026. The pharmaceutical company's wholly-owned subsidiary board has given formal consent for merging Alkem Medtech Ortho Private Limited with Alkem Medtech Private Limited through a scheme of arrangement.

Merger Structure and Financial Details

The proposed merger involves consolidation of two subsidiaries operating in the medical technology space, with significant differences in their financial positions. The board's approval represents a formal step in the corporate restructuring process under Sections 230 to 232 of the Companies Act, 2013.

Business Operations and Rationale

The transferor company, Alkem Medtech Ortho Private Limited, is primarily engaged in manufacturing, producing, trading, importing and exporting orthopedic surgery equipment and joint implants. The transferee company, Alkem Medtech Private Limited, operates in manufacturing, importing, exporting and marketing of medical, surgical and dental equipment.

Regulatory Approval Process

The merger requires sanction from both Mumbai and Ahmedabad benches of the National Company Law Tribunal (NCLT). The scheme is subject to requisite approvals from shareholders and creditors if directed by NCLT, along with compliance with applicable laws and other required approvals.

Strategic Impact

The consolidation will eliminate multiplicity of legal and regulatory compliances while creating a streamlined management structure. The combined entity will possess a broader product portfolio, strengthening its presence in key therapeutic segments and geographic markets through optimized distribution networks.